LZLin Zhou

Lin Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lin Zhou has a total of 71 co-authors. Here are the top co-authors by number of shared publications:

  • Yong Xu

    Department of Radiation Oncology, Division of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China

    4 shared publications
  • You Lu

    Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China

    4 shared publications
  • Jianxin Xue

    Department of Thoracic Oncology, Cancer Center, West China hospital, Sichuan University, Chengdu, 610041, China

    3 shared publications
  • Yongmei Liu

    Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China

    3 shared publications
  • Youling Gong

    Department of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, P.R. China

    3 shared publications
  • Jia Liu

    Department of Oncology, Chengdu First People’s Hospital, Chengdu, Sichuan, China

    2 shared publications

Latest Publications

  • Open Access

    Editorial: Treatment of brain metastases from non-small cell lung cancer: preclinical, clinical, and translational research

    by Jia Liu, Pengfei Zhou, Lei Deng, Jianxin Xue, Lin Zhou

    Non-small cell lung cancer (NSCLC) is the most common malignancy worldwide, with up to 50% of patients developing brain metastases (BMs) in their disease course and 70% of BMs developing multiple lesions (1). BMs have a significant negative impact on both survival and quality of life for patients with NSCLC. The present research topic, which included 15 articles, aims to present new evidence for preclinical, translational, and clinical studies in NSCLC with BMs. Furthermore, immunotherapies, such as checkpoint inhibitors, also demonstrate some effectiveness.The pathological subtypes of NSCLC may be correlated with the occurrence and prognosis of BMs.adenocarcinomas of distinct pathological subtypes. Clinical data from 156 patients were collected and analysed. Patients were classified into two groups on the basis of pathological subtype: moderately to highly differentiated and poorly differentiated. The median overall survival (mOS) for the poorly differentiated group was 14.67 months (95% CI: 11.80-17.53 months), whereas it was 25.00 months (95% CI: 19.55-30.45 months) for the moderately to highly differentiated group (hazard ratio [HR] of 1.55, 95% CI: 1.06-2.25; p = 0.023). However, this study did not provide data on driver gene mutations or programmed death-ligand 1 (PD-L1) expression, which are established prognostic factors for NSCLC with BMs, and the prevalence of gene mutations and PD-L1 may vary across different pathological subtypes and influence the therapeutic effect (2-4). Wu et al.reported that pathological subtypes, together with sex, leukocyte count, and fibrinogen stage, were independent risk factors for predicting BMs in lung cancer patients. However, this study also did not provide data on driver gene mutations, which have been reported as risk factors for BMs in NSCLC (5).TKIs serve as the cornerstone of treatment for driver gene-positive, such as epidermal growth factor receptor (EGFR)-mutant and anaplastic lymphoma kinase (ALK) rearrangement, NSCLC with BMs.In particular, new-generation TKIs exhibit high blood-brain barrier permeability and demonstrate superior efficacy against BMs (6,7). As a result, brain metastases are no longer a critical prognostic factor for this patient population. Li et al. compared the prognoses of synchronous and metachronous BMs from NSCLC and reported that synchronous BMs (HR: 1.335, 95% CI: 1.076-1.657, p = 0.009), squamous carcinoma (HR: 1.361, 95% CI: 1.018-1.820, p = 0.037), and KPS score < 80 (HR: 1.392, 95% CI: 1.124-1.724, p = 0.002) were risk factors for OS. Interestingly, for patients with EGFR mutations, there was no significant difference in OS between synchronous and metachronous BMs (p = 0.270), which might indicate that the timing of BMs does not affect the prognosis of patients with EGFR mutations.There have been numerous studies on the application of radiomics in NSCLC patients with BMs.Radiomics models based on multiparametric MRI can effectively predict the primary origin of brain metastases, clinical benefit, and progression-free survival (PFS) of immunotherapy for NSCLC patients with BMs (8,9), and bimodal radiomics with CT and MRI (combining primary and BMs) achieves 86.7% accuracy in predicting the EGFR status (10). Similarly, Jiang et al. used CT perfusion imaging to predict pathological types of NSCLC with BMs, and reported that adenocarcinoma and squamous carcinoma patients presented significant differences in cerebral It has been reported that peritumoral brain edema is correlated with prognosis, with extensive or prolonged edema duration generally associated with poorer outcomes (13,14). Arrieta et al. investigated the predictive value of perilesional edema diameter (PED) associated with BMs for radiotherapy response in NSCLC patients, and reported that minor PED was independently associated with a better intracranial objective response rate (78.8% vs. 50%, OR 3.71, p = 0.018), longer median iPFS (11.8 vs. 6.9 months, HR 2.9, p < 0.001), and longer median OS (18.4 vs. 7.9 months, HR 2.1, p = 0.001). Cerebral radiation necrosis (CRN) is a relatively common late toxicity that severely influences patients' quality of life following radiotherapy for BMs. The incidence rate of CRN after brain SRT/SRS for BMs has been reported to be 6.3-34% (15)(16)(17). Several studies have indicated that bevacizumab alleviates inflammatory responses and clinical symptoms in patients with CRN by inhibiting vascular endothelial growth factor (VEGF), thereby reducing vascular permeability and cerebral edema (18,19). Zhang et al. explored whether bevacizumab could prevent CRN in NSCLC patients with BMs undergoing SRT, and reported that bevacizumab significantly reduced the incidence of CRN and/or symptomatic edema before (p = 0.036) and after (p = 0.015) inverse probability of treatment weighting (IPTW) adjustment.The phase III FLAURA2 trial demonstrated that, compared with first-line osimertinib monotherapy, first-line osimertinib plus chemotherapy improved PFS (HR=0.62, 95% CI 0.49-0.79, p < 0.001) and CNS-PFS (HR=0.58, 95% CI 0.33-1.01) (20,21). Chen et al. performed a meta-analysis to compare the efficacy and safety of combining chemotherapy with EGFR-TKIs (ETC) versus EGFR-TKIs monotherapy for EGFR-mutated NSCLC patients with BMs; the meta-analysis included seven studies based on five randomized clinical trials with 550 patients, and revealed that the ETC group had better OS (HR: 0.64 [0.48, 0.87]), PFS (HR: 0.42 [0.34, 0.52]), and central nervous system PFS (HR: 0.42 [0.31, 0.57]). However, the patients in the ETC group experienced more grade 3-5/serious adverse events. The previous meta-analysis suggested that immunotherapy combined with chemotherapy yielded a better objective response rate (ORR), PFS, and OS than immunotherapy alone for PD-L1-negative and driver-gene-negative nonsquamous NSCLC (22). Brown et al. assessed first-line chemoimmunotherapy and immunotherapy in NSCLC patients with BMs via data from the...

  • Using a zebrafish xenograft tumor model to compare the efficacy and safety of VEGFR-TKIs

    by Hou Wanting, Zhong Jian, Xiao Chaoxin, Yi Cheng, Zhao Chengjian, Zhou Lin, Cao Dan

    Purpose We constructed a zebrafish xenograft tumor model to compare and quantify the antiangiogenic efficacy and safety of nine vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs), axitinib, lenvatinib, pazopanib, apatinib, cabozantinib, sunitinib, semaxanib, sorafenib, and regorafenib, in parallel. Methods CT26 and GL261 tumor cells were implanted into the perivitelline space of Tg (flk1: eGFP) zebrafish to construct a xenograft tumor model. VEGFR-TKIs’ antiangiogenic efficacy was quantified using AngioTool software, and the median effective dose (ED50) was calculated. The toxicity was evaluated by calculating the median lethal dose (LD50) and gross morphological changes. Cardiac toxicity was further assessed by heart rate, heart rhythm, the distance between the sinus venosus (SV) and bulbus arteriosus (BA), and pericardial edema. Results Using the zebrafish xenograft tumor model, we found that all nine VEGFR-TKIs exhibited antiangiogenic abilities, but the effectiveness of semaxanib was worse than that of other VEGFR-TKIs. Meanwhile, the zebrafish toxicity assay showed that all tested VEGFR-TKIs were associated with cardiac-related toxicity, especially apatinib and axitinib, which caused serious pericardial edema in zebrafish at relatively low concentrations. A narrow therapeutic window was found for most VEGFR-TKIs, and the simultaneous occurrence of toxic effects of semaxanib was recognized. Conclusion Our findings showed the potential of using a zebrafish xenograft tumor model to accelerate VEGFR-TKI screening and further the development of more efficient and less toxic VEGFR-TKIs.


  • Open Access

    Identification of the miRNA-mRNA regulatory network associated with radiosensitivity in esophageal cancer based on integrative analysis of the TCGA and GEO data

    by Hongmin Chen, Xiaoxiao Shi, Li Ren, Hongyu Zhuo, Li Zeng, Qing Qin, Yuming Wan, Wangmu Sangdan, Lin Zhou

    Background: The current study set out to identify the miRNA-mRNA regulatory networks that influence the radiosensitivity in esophageal cancer based on the The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. Methods: Firstly, esophageal cancer-related miRNA-seq and mRNA-seq data were retrieved from the TCGA database, and the mRNA dataset of esophageal cancer radiotherapy was downloaded from the GEO database to analyze the differential expressed miRNAs (DEmiRNAs) and mRNAs (DEmRNAs) in radiosensitive and radioresistant samples, followed by the construction of the miRNA-mRNA regulatory network and Gene Ontology and KEGG enrichment analysis. Additionally, a prognostic risk model was constructed, and its accuracy was evaluated by means of receiver operating characteristic analysis. Results: A total of 125 DEmiRNAs and 42 DEmRNAs were closely related to the radiosensitivity in patients with esophageal cancer. Based on 47 miRNA-mRNA interactions, including 21 miRNAs and 21 mRNAs, the miRNA-mRNA regulatory network was constructed. The prognostic risk model based on 2 miRNAs (miR-132-3p and miR-576-5p) and 4 mRNAs (CAND1, ZDHHC23, AHR, and MTMR4) could accurately predict the prognosis of esophageal cancer patients. Finally, it was verified that miR-132-3p/CAND1/ZDHHC23 and miR-576-5p/AHR could affect the radiosensitivity in esophageal cancer. Conclusion: Our study demonstrated that miR-132-3p/CAND1/ZDHHC23 and miR-576-5p/AHR were critical molecular pathways related to the radiosensitivity of esophageal cancer.


  • Open Access

    The nomograms to predict early death among metastatic small-cell lung cancer patients: a retrospective study based on SEER database

    by Tao Hai, Lin Zhou, Jingqiu Wang, Hao Wei, Yishun Wang, Tian Tian, Wangchun Wu, Ting Mei

    Original Article The nomograms to predict early death among metastatic small-cell lung cancer patients: a retrospective study based on SEER database Tao Hai, Lin Zhou, Jingqiu Wang, Hao Wei, Yishun Wang, Tian Tian, Wangchun Wu, Ting Mei


  • Development and validation of a nomogram for assessing survival in extensive-stage small-cell lung cancer patients with superior vena cava syndrome referred for thoracic radiotherapy: a comparison of upfront vs. consolidative approaches

    by Ting Mei, Weigang Xiu, Xuexi Yang, Xiaoman Tian, Yang Yu, Yong Xu, Lin Zhou, Xiaojuan Zhou, Yongmei Liu, Bingwen Zou, et al.

    Purpose This study sought to design and validate a nomogram capable of predicting outcomes in extensive-stage small-cell lung cancer (ES-SCLC) patients with superior vena cava syndrome (SVCS) based upon the timing of their radiotherapy treatment. Methods We retrospectively analyzed data from 175 ES-SCLC patients with SCVS, comparing outcomes between those that underwent upfront thoracic radiotherapy (initial radiotherapy with simultaneous chemotherapy) and those that underwent consolidative thoracic radiotherapy (following 4–6 cycles of chemotherapy). Significant predictors of patient outcomes were identified using a Cox proportional hazard model and were used to construct our nomogram. This model was subsequently validated using receiver operating characteristic (ROC) curves, concordance index (C-index) values, and a risk classification system in order to evaluate its discriminative and predictive accuracy. Results The overall survival (OS) of ES-SCLC patients with SVCS that underwent chemotherapy (CT), consolidative thoracic radiotherapy (cc-TRT), and upfront thoracic radiotherapy (cu-TRT) was 8.2, 11.7, and 14.9 months, respectively (p < 0.001), with respective progression-free survival (PFS) durations of 3.3, 5.0, and 7.3 months (p < 0.001). A multivariate regression analysis revealed age, gender, ECOG performance status, sites of tumor metastasis, and treatment approach to all be independent predictors of survival outcomes. A nomogram was therefore developed incorporating these factors. C‑index values upon internal and external validation of this nomogram were 0.7625 and 0.7959, respectively, and ROC and calibration curves revealed this model to be accurate and consistent. Conclusions We found that upfront thoracic radiotherapy in combination with chemotherapy may be associated with a positive impact on outcomes in ES-SCLC patients with SVCS.


  • Effective method to reduce the normal brain dose in single-isocenter hypofractionated stereotactic radiotherapy for multiple brain metastases

    by Jialu Lai, Jia Liu, Jianling Zhao, An Li, Shoupeng Liu, Zhonghua Deng, Qiaoyue Tan, Haitao Wang, Yuming Jia, Kaijian Lei, et al.

    Background and purpose Island blocking and dose leakage problems will lead to unnecessary irradiation to normal brain tissue (NBT) in hypofractionated stereotactic radiotherapy (HSRT) for multiple brain metastases (BM) with single-isocenter volumetric modulated arc therapy (VMAT). The present study aimed at investigating whether reducing the number of metastases irradiated by each arc beam could minimize these two problems. Materials and methods A total of 32 non-small-cell lung cancer (NSCLC) patients with multiple BM received HSRT (24–36 Gy/3 fractions) with single-isocenter VMAT, where each arc beam only irradiated partial metastases (pm-VMAT), were enrolled in this retrospective study. Conventional single-isocenter VMAT plans, where each arc beam irradiated whole metastases (wm-VMAT), was regenerated and compared with pm-VMAT plans. Furthermore, the clinical efficacy and toxicities were evaluated. Results Pm-VMAT achieved similar target coverage as that with wm-VMAT, with better dose fall-off (P < 0.001) and NBT sparing (P < 0.001). However, pm-VMAT resulted in more monitor units (MU) and longer beam-on time (P < 0.001). The intracranial objective response rate and disease control rate for all patients were 75% and 100%, respectively. The local control rates at 1 year and 2 year were 96.2% and 60.2%, respectively. The median progression-free survival and overall survival were 10.3 months (95% confidence interval [CI] 6.8–13.2) and 18.5 months (95% CI 15.9–20.1), respectively. All treatment-related adverse events were grade 1 or 2, and 3 lesions (2.31%) from 2 patients (6.25%) demonstrated radiation necrosis after HSRT. Conclusion HSRT with pm-VMAT is effective and has limited toxicities for NSCLC patients with multiple BM. Pm-VMAT could provide better NBT sparing while maintaining target dose coverage.


  • Open Access

    Stereotactic body radiation therapy for post-pulmonary lobectomy isolated lung metastasis of thoracic tumor: survival and side effects

    by Weijie Xiong, Qingfeng Xu, Yong Xu, Changjin Sun, Na Li, Lin Zhou, Yongmei Liu, Xiaojuan Zhou, Yongsheng Wang, Jin Wang, et al.

    Stereotactic body radiation therapy (SBRT) has emerged as an alternative treatment for patients with early stage non-small cell lung cancer (NSCLC) or metastatic pulmonary tumors. However, for isolated lung metastasis (ILM) of thoracic malignances after pulmonary lobectomy, reported outcomes of SBRT have been limited. This study evaluates the role of SBRT in the treatment of such patients. A retrospective search of the SBRT database was conducted in three hospitals. The parameters analyzed in the treated patients were local control, progression-free survival (PFS), overall survival (OS), and the treatment-related side-effects. In total, 23 patients with single ILM after pulmonary lobectomy treated with SBRT were identified and the median follow-up time was 14 months (range: 6.0-47.0 months). Local recurrences were observed in two patients during follow-up and the 1-year local control rate was 91.3%. Median PFS and OS for the studied cohort were 10.0 months [95% confidence interval (CI) 5.1-14.9 months] and 21.0 months (95% CI 11.4-30.6 months), respectively. Acute radiation pneumonitis (RP) of grade 2 or worse was observed in five (21.7%) and three (13.0%) patients, respectively. Other treatment-related toxicities included chest wall pain in one patient (4.3%) and acute esophagitis in two patients (8.7%). By Pearson correlation analysis, the planning target volume (PTV) volume and the volume of the ipsilateral lung exposed to a minimum dose of 5 Gy (IpV5) were significantly related to the acute RP of grade 2 or worse in present study (p < 0.05). The optimal thresholds of the PTV and IpV5 to predict RP of acute grade 2 or worse RP were 59 cm3 and 51% respectively, according to the receiver-operating characteristics curve analysis, with sensitivity/specificity of 75.0%/80.0% and 62.5%/80.0%. SBRT for post-lobectomy ILM was effective and well tolerated. The major reason for disease progression was distant failure but not local recurrence. The PTV and IpV5 are potential predictors of acute RP of grade 2 or higher and should be considered in treatment planning for such patients.


  • Open Access

    Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer

    by Lin Zhou, Jia Liu, Jianxin Xue, Yong Xu, Youling Gong, Lei Deng, Shichao Wang, Renming Zhong, Zhenyu Ding, You Lu

    Whole brain radiotherapy (WBRT) plus sequential focal radiation boost is a commonly used therapeutic strategy for patients with brain metastases. However, recent reports on WBRT plus simultaneous in-field boost (SIB) also showed promising outcomes. The objective of present study is to retrospectively evaluate the efficacy and toxicities of WBRT plus SIB with image guided intensity-modulated radiotherapy (IG-IMRT) for inoperable brain metastases of NSCLC. Twenty-nine NSCLC patients with 87 inoperable brain metastases were included in this retrospective study. All patients received WBRT at a dose of 40 Gy/20 f, and SIB boost with IG-IMRT at a dose of 20 Gy/5 f concurrent with WBRT in the fourth week. Prior to each fraction of IG-IMRT boost, on-line positioning verification and correction were used to ensure that the set-up errors were within 2 mm by cone beam computed tomography in all patients. The one-year intracranial control rate, local brain failure rate, and distant brain failure rate were 62.9%, 13.8%, and 19.2%, respectively. The two-year intracranial control rate, local brain failure rate, and distant brain failure rate were 42.5%, 30.9%, and 36.4%, respectively. Both median intracranial progression-free survival and median survival were 10 months. Six-month, one-year, and two-year survival rates were 65.5%, 41.4%, and 13.8%, corresponding to 62.1%, 41.4%, and 10.3% of intracranial progression-free survival rates. Patients with Score Index for Radiosurgery in Brain Metastases (SIR) >5, number of intracranial lesions <3, and history of EGFR-TKI treatment had better survival. Three lesions (3.45%) demonstrated radiation necrosis after radiotherapy. Grades 2 and 3 cognitive impairment with grade 2 radiation leukoencephalopathy were observed in 4 (13.8%) and 4 (13.8%) patients. No dosimetric parameters were found to be associated with these late toxicities. Patients received EGFR-TKI treatment had higher incidence of grades 2–3 cognitive impairment with grade 2 leukoencephalopathy. WBRT plus SIB with IG-IMRT is a tolerable and effective treatment for NSCLC patients with inoperable brain metastases. However, the results of present study need to be examined by the prospective investigations.


  • Open Access

    Implementation of single-breath-hold cone beam CT guided hypofraction radiotherapy for lung cancer

    by Renming Zhong, Jin Wang, Lin Zhou, Feng Xu, Li Liu, Jidan Zhou, Xiaoqin Jiang, Nianyong Chen, Sen Bai, You Lu

    To analyze the feasibility of active breath control (ABC), the lung tumor reproducibility and the rationale for single-breath-hold cone beam CT (CBCT)-guided hypofraction radiotherapy. Single-breath-hold CBCT images were acquired using ABC in a cohort of 83 lung cancer patients (95 tumors) treated with hypofraction radiotherapy. For all alignments between the reference CT and CBCT images (including the pre-correction, post-correction and post-treatment CBCT images), the tumor reproducibility was evaluated via online manual alignment of the tumors, and the vertebral bone uncertainties were evaluated via offline manual alignment of the vertebral bones. The difference between the tumor reproducibility and the vertebral bone uncertainty represents the change in the tumor position relative to the vertebral bone. The relative tumor positions along the coronal, sagittal and transverse axes were measured based on the reference CT image. The correlations between the vertebral bone uncertainty, the relative tumor position, the total treatment time and the tumor reproducibility were evaluated using the Pearson correlations. Pre-correction, the systematic/random errors of tumor reproducibility were 4.5/2.6 (medial-lateral, ML), 5.1/4.8 (cranial-caudal, CC) and 4.0/3.6 mm (anterior-posterior, AP). These errors were significantly decreased to within 3 mm, both post-correction and post-treatment. The corresponding PTV margins were 4.7 (ML), 7.4 (CC) and 5.4 (AP) mm. The changes in the tumor position relative to the vertebral bone displayed systematic/random errors of 2.2/2.0 (ML), 4.1/4.4 (CC) and 3.1/3.3 (AP) mm. The uncertainty of the vertebral bone significantly correlated to the reproducibility of the tumor position (P < 0.05), except in the CC direction post-treatment. However, no significant correlation was detected between the relative tumor position, the total treatment time and the tumor reproducibility (P > 0.05). Using ABC for single-breath-hold CBCT guidance is an effective method to reduce the PTV margin of hypofraction radiotherapy for lung cancer. Using ABC, the tumor position was significantly altered relative to the vertebral position. The reproducibility of the tumor position was affected by the vertebral bone but not by the relative tumor position or the total treatment time.


  • Open Access

    Paclitaxel and cisplatin combined with intensity-modulated radiotherapy for upper esophageal carcinoma

    by Lingli Tu, Lan Sun, Yong Xu, Yongsheng Wang, Lin Zhou, Yongmei Liu, Jiang Zhu, Feng Peng, Yuquan Wei, Youling Gong

    This study was conducted to evaluate the effectiveness and safety of intensity-modulated radiotherapy (IMRT) and concurrent paclitaxel plus cisplatin (TP regimen) for upper esophageal carcinoma. 36 patients of upper esophageal carcinoma were retrospectively analyzed. Patients were treated with IMRT (median 60 Gy) combined with concurrent TP regimen chemotherapy. The Kaplan-Meier analysis was performed in statistical analysis. Toxicities were recorded according to the NCI CTC version 3.0. 36 patients aged 43–73 years (median 57 years). The median follow-up period was 14.0 months. The 1-year and 2-year survival rates were 83.3% and 42.8% respectively. The median progression-free survival (PFS) time and overall survival (OS) time were 12.0 (95% CI: 7.8–16.2 months) and 18.0 months (95% CI: 9.9–26.1 months), respectively. Grade 3 neutropenia, radiation-induced esophagitis and radiodermatitis were observed in 5 (13.9%), 3 (8.3%) and 8 (22.2%) patients respectively. There were two treatment-related deaths due to esophageal perforation and hemorrhea. For those patients with upper esophageal carcinoma, IMRT combined with concurrent TP regimen chemotherapy was an effective treatment. However, more attention should be paid to the occurrence of perforation and hemorrhea.